Affimed and Dyax Cross-License Antibody Technologies
Affimed Therapeutics AG and Dyax Corp. announced today that they have entered into a cross-licensing agreement for phage display technologies. Financial terms were not disclosed.
The Affimed licensed patents consist of two issued U.S. patents with broad claims. They cover the generation of human antibody libraries derived from the IgM repertoire of the immune system, which is considered to be the most diverse naturally occurring repertoire of antibody genes, and the generation of synthetic antibody libraries.
Dyax's Ladner patents have the earliest priority date for phage display patents in the United States and are the core patents in phage display technology. With four granted patents in the United States, Dyax has over 60 licensees to the Ladner patents, making this patent licensing program one of the most widely licensed in the biotechnology industry. The Ladner patents cover the practice of display technologies, including the display of antibodies, peptides, and proteins on any cell, spore, or virus, including bacteriophage.
Peter Fuhge, CEO of Affimed Therapeutics AG, commented: "The cross-licensing agreement with Dyax significantly strengthens our proprietary technology platform for developing therapeutic products using our high quality antibody libraries. This represents another important step on the way to becoming a complete antibody technology company."
"Natural diversity from the IgM repertoire has important advantages over purely synthetic diversity or other natural antibody repertoires," said Henry E. Blair, Chairman and CEO of Dyax Corp. "This agreement is an extension of our strategy to bring a broader intellectual property base and improved technology to both our customers and our internal Dyax antibody development programs."
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
Scientists identify gene for resistance to parasitic 'witchweed'
AEterna Zentaris Announces Completion of Patient Enrollment for Ozarelix Phase II Trial in Benign Prostatic Hyperplasia
Reverse negative impact of ultraviolet radiation on skin
Algeta completes enrolment of 900 patients into phase III ALSYMPCA trial with Alpharadin - Primary endpoint is overall survival in castration-resistant prostate cancer (CRPC) patients with bone metastases
